Search Within

Carlyn Rose Tan

Formats
  1. Meeting Abstract (104)
  2. Journal Article (23)
  3. Research Letter (7)
  4. Correspondence (3)
  5. Review (3)
Groups
  1. Hematologic Malignancies, Division of (140)
  2. Department of Medicine (123)
  3. Center for Hematologic Malignancies (122)
  4. Myeloma (120)
  5. Survivorship Research (120)
  6. CTCR Scholars (119)

More Groups

People
  1. Alexander Lesokhin (118)
  2. Sham Mailankody (118)
  3. Urvi Shah (118)
  4. Malin Hultcrantz (117)
  5. Hani Hassoun (116)
  6. Neha Korde (116)

More People

Years
  1. 2025 (6)
  2. 2024 (44)
  3. 2023 (41)
  4. 2022 (29)
  5. 2021 (13)
  6. 2020 (7)
Publications
  1. Blood (54)
  2. Clinical Lymphoma, Myeloma and Leukemia (41)
  3. Journal of Clinical Oncology (9)
  4. Blood Cancer Journal (6)
  5. American Journal of Hematology (4)
  6. Blood Advances (4)

More Publications

Publishers
  1. American Society of Hematology (58)
  2. Elsevier Inc. (43)
  3. American Society of Clinical Oncology (9)
  4. Nature Publishing Group (8)
  5. John Wiley & Sons, Inc. (4)
  6. Taylor & Francis Group (3)

More Publishers

Results (140)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A pilot plant based dietary intervention in MGUS and SMM patients with elevated BMI is feasible and associated with improvements in metabolic and microbiome biomarkers of progression
    Meeting Abstract

    Shah, U. A.; Derkach, A.; Castro, F.; Anuraj, A.; Blaslov, J.; Tran, L.; Adintori, P. A.; Burge, M.; Funkhouser, S.; Hosszu, K.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase 2 trial of colesevelam for lenalidomide-associated diarrhea
    Meeting Abstract

    Hultcrantz, M.; Hassoun, H.; Korde, N.; Mailankody, S.; Shekarkhand, T.; Burge, M.; Maclachlan, K. H.; Patel, D.; Shah, U. A.; Chung, D. J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Carfilzomib, lenalidomide and dexamethasone (KRd) vs bortezomib, lenalidomide, and dexamethasone (VRd) as induction therapy in newly diagnosed high-risk multiple myeloma
    Meeting Abstract

    Tan, C.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Patel, D.; Maclachlan, K. H.; Lahoud, O. B.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Genomic determinants of resistance in newly diagnosed multiple myeloma treated with targeted-immunotherapy
    Meeting Abstract

    Maura, F.; Boyle, E.; Coffey, D.; Maclachlan, K. H.; Diamond, B.; Blaney, P.; Gagler, D.; Ziccheddu, B.; Ghamlouch, H.; Wang, Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Fc-mediated antibody effector function, inflammation resolution and oligoclonality on TCR rearrangements predict sustained MRD negativity in newly diagnosed multiple myeloma treated with immunotherapy regimens
    Meeting Abstract

    Boyle, E. M.; Maura, F.; Coffey, D.; Maclachlan, K. H.; Diamond, B.; Ghamlouch, H.; Gagler, D.; Blaney, P.; Ziccheddu, B.; Wang, Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Stem cell autograft minimal residual disease negativity improves outcomes after autotransplant for multiple myeloma
    Meeting Abstract

    Nishimura, N.; Brown, S.; Devlin, S. M.; Dahi, P. B.; Landau, H.; Lahoud, O. B.; Scordo, M.; Shah, G. L.; Hassoun, H.; Hultcrantz, M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy
    Correspondence

    Nath, K.; Shekarkhand, T.; Salcedo, M.; Derkach, A.; Rueda, S.; Chansakul, A.; Hulcrantz, M.; Korde, N.; Shah, U. A.; Tan, C.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Sustained minimal residual disease negativity in multiple myeloma is associated with stool butyrate and healthier plant-based diets
    Journal Article

    Shah, U. A.; Maclachlan, K. H.; Derkach, A.; Salcedo, M.; Barnett, K.; Caple, J.; Blaslov, J.; Tran, L.; Ciardiello, A.; Burge, M.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Clinical efficacy of daratumumab (DARA)-based second line therapy after DARAcontaining and DARA-free induction therapies in multiple myeloma: A single center experience
    Meeting Abstract

    Ciardiello, A.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Lu, S. X.; Patel, D.; Maclachlan, K.; Lahoud, O. B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • African American patients with smoldering multiple myeloma may have a lower risk of progression compared to White patients
    Meeting Abstract

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A. M.; Hassoun, H.; Lu, S. X.; Patel, D.; Shah, U. A.; Tan, C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save